Livmoniplimab

5 trials 3 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

2 Completed trials

1 Sponsors

7 Countries

Phase II/III

Phase II

Phase I

Phase II/III: 2 Phase II: 2 Phase I: 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 5

All trials

5 total

A Study to Assess Livmoniplimab in Combination with Budigalimab Versus Chemotherapy in Adult Participants with Metastatic Urothelial Carcino… Recruiting

2024-515506-11-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chem… Recruiting

2023-505773-32-00 Phase II/III 4 countries AbbVie Deutschland GmbH & Co. KG
Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga… Recruiting

2023-504600-28-00 Phase II/III 3 countries AbbVie Deutschland GmbH & Co. KG
Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Co… Ended

2022-502948-13-00 Phase II 3 countries Abbvie Deutschland GmbH & Co. KG
Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Sub… Ended

2023-508281-15-00 Phase I 6 countries AbbVie Deutschland GmbH & Co. KG

Showing 1–5 of 5 trials

← All drugs A–Z